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i 
Abstract 
Cardiac output, the volume of blood pumped by the heart over time, is a powerful 
clinical metric used by physicians to assess overall cardiac health and patient well-being. 
However, current cardiac output estimation methods are typically invasive, time-consuming, 
expensive, or some combination of all three. Patients that receive artificial cardiac pacemaker 
devices are particularly susceptible to cardiac dysfunction and often require long-term cardiac 
monitoring support.   
This thesis proposes a novel cardiac output monitoring solution which leverages an 
implantable intracardiac medical device. The principles of traditional impedance cardiography, 
an established cardiac output monitoring technique in practice for over fifty years, have been 
adapted to incorporate a leadless artificial cardiac pacemaker, an implantable medical device 
contained entirely within the heart. This novel method, colloquially referred to as Z-Cardio, 
monitors time-varying intracardiac impedance modulation to assess changes in cardiac output. 
In this study, technologies both old and new are synthesized to produce a novel and effective 
method of monitoring a critical metric of cardiac health. 
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Preface 
The purpose of this thesis is to clearly and concisely describe a system designed to 
monitor changes in cardiac output, the volume of blood that flows through the heart. This 
thesis would not have been possible without a sound understanding of both electrical and 
mechanical principles that govern our heart’s function. Living systems balance remarkably 
intricate components in the desperate struggle for mere temporary survival. Despite the 
complexity and variability of the interconnecting systems within even a single organism, few 
are as intimately tied to our own human sense of well-being as our own beating heart. Over 
an average lifetime, the human heart will contract nearly four billion times, pumping 
approximately one quarter of a billion liters of blood throughout a single body. Unwavering 
in consistency, the ever-present beating within our chests has assured even our earliest human 
ancestors of their own vitality and liveliness. Incredibly, for the vast majority of us, our hearts 
pump virtually nonstop and without failure for all but the absolute final moments of existence.  
Unfortunately, such a system is not without fault. For many reasons, the heart can and 
does break down. If a heart becomes incapable of supplying a body with oxygen-rich blood, 
the body’s carefully maintained metabolic balance may begin to collapse. Understanding 
whether our hearts are pumping enough blood is the principle motivation for the investigation 
that I have undertaken. The objective of this thesis is to build upon existing technology and 
to establish a new method of cardiac performance assessment. Through this, I seek to provide 
greater insight into the intimate and incredible organ that we all share.  
 
 
1 
1. Introduction 
Cardiac output measures the rate of blood flow through the heart by relating the 
volume of blood ejected from the heart in a single contraction and the rate at which the heart 
contracts. For a typical healthy man and women, nominal cardiac output is approximately 5.6 
and 4.9 liters per minute, respectively [1]. While a healthy heart is adequately capable of 
supplying oxygen-rich blood to the body, a decrease in cardiac output over time may indicate 
heart failure, necessitating therapeutic intervention such as implanting an artificial cardiac 
pacemaker [2]. Doctors interested in monitoring their patients’ cardiac output are faced with 
a variety of methods to choose from. Patients who have already received an artificial cardiac 
pacemaker would benefit from a device capable of accurately monitoring changes in cardiac 
output over time, providing physicians a powerful tool in developing treatment options for 
their patients [3]. This thesis explores a novel method by which an implanted medical device 
may assess changes in cardiac output by monitoring changes in the electrical impedance across 
an electric dipole located within the right ventricle. To better facilitate the reader’s 
understanding of the principles described in this thesis, a background in human cardiac 
physiology, the artificial cardiac pacemaker, and the relevant biophysical principles is provided. 
1.1. Review of Cardiac Physiology 
The mammalian circulatory system is driven by the heart, the body’s principal pump 
of both oxygen and nutrients throughout the body. This section will introduce the high-level 
principles of cardiac operation by discussing the mechanical, electrical, and chemical behavior 
of the human heart.  
This thesis is concerned with three primary cardiac metrics: heart rate, stroke volume, 
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and cardiac output. Heart rate (HR) is the rate at which the heart contracts. Heart rate is 
typically measured in beats per minute and can vary significantly between individuals but 
typically rests around 70 beats per minute [4]. The heart’s stroke volume (SV), typically 
measured in milliliters, is the volume of blood ejected from the heart in a single heartbeat, 
approximately 70 milliliters in a healthy human male. Cardiac output (CO) is the total volume 
of blood pumped through the heart over unit time, typically measured in liters per minute, and 
rests at approximately 5 liters per minute in a healthy human male. The following sections will 
discuss the physiology governing these metrics, challenges associated when any of these 
metrics begins to collapse, and treatment options available to provide cardiac output 
monitoring support. This chapter concludes with a brief discussion of contributions made by 
the author and outlines the organization of the rest of this thesis. 
1.1.1. The Heart as a Mechanical System 
The human heart is divided into four pumping chambers [5]. The cyclical and 
coordinated contraction of the four chambers is referred to as the cardiac cycle. The cardiac 
cycle is divided into two distinct phases. The diastolic phase, or diastole, refers to time during 
which the heart is relaxing; the systolic phase, or systole, refers to time during which the heart 
is contracting and ejecting blood. Following the flow of blood through the heart in Figure 1, 
deoxygenated venous blood first returns from the body to the heart through the superior vena 
cava (SVC) and the inferior vena cava (IVC), which are located above and below the heart, 
respectively. These two great veins draw blood from everywhere else in the body and deliver 
blood to the heart’s right atrium (RA). The RA contracts to deliver blood through the tricuspid 
valve to prime the right ventricle (RV) for contraction. The right ventricle pumps blood 
through the pulmonary valve, through the pulmonary arteries, and into the oxygen-supplying 
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lungs. Newly oxygenated blood returns to the heart from the lungs through the pulmonary 
veins, which join at the left atrium (LA). The LA pumps oxygen-rich blood through the mitral 
valve and into the left ventricle (LV), priming the largest and most powerful chamber of the 
heart to efficiently deliver blood throughout the rest of the body. As the muscular left ventricle 
contracts, blood is forced out of the heart through the aortic valve, through the aorta, and out 
to the body’s systemic tissue. Through this cycle, energy is transferred to the blood, providing 
enough velocity and pressure to reach systemic tissue within the body to deliver oxygen and 
nutrients, fulfillinh metabolic demand. 
 
Figure 1: Basic cardiac anatomy. Blue components indicate de-oxygenated blood pathways and red 
components indicate oxygenated blood pathways (Wikimedia Commons ZooFari/CC BY-SA 3.0) 
The heart requires its own supply of oxygenated blood to function properly. The 
coronary vascular system supplies the heart with its own blood by drawing oxygenated blood 
directly from the aorta, diffusing oxygen through coronary vasculature, and expelling 
deoxygenated blood directly into the right atrium through the coronary sinus. A myocardial 
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infarction, commonly referred to as a heart attack, typically describes a sudden blockage within 
a coronary artery, which may result in cellular necrosis or complete cardiac arrest [6]. 
1.1.2. The Heart as an Electrical System 
The heart is controlled by both extrinsic and intrinsic electrical activity. The autonomic 
nervous system controls the heart’s rate of contraction (chronotropy), neural conduction 
velocity (dromotropy), and myocardial tissue contractility (inotropy). Electrical impulses travel 
from the brain and down the Vagus nerve, which innervates the heart with both sympathetic 
and parasympathetic neural fibers. Together, the competing sympathetic and parasympathetic 
systems control and modulate cardiac neural tone [7].  
The heart’s rhythmic cardiac cycle is controlled by electrical impulses originating from 
the sinoatrial (SA) node within the heart. The SA impulse propagates around the right and 
then left atrium, inducing atrial contraction, before rejoining at the atrioventricular (AV) node, 
located between the right atrium and right ventricle. From the AV node, the impulse travels 
downward through the Bundle of His, a dense neural structure that runs through the center 
of the ventricular septum. As the impulse reaches the apex of the heart, it branches into the 
left and right bundle branches before reversing direction, travelling back up through the outer 
walls of both the right and the left ventricle. The left and right bundles splinter into Purkinje 
Fibers, which fully innervate both the left and right ventricles. As electrical signals induce 
contraction in this way, a controllable, predictable, and synchronized cardiac motion results. 
A detailed wiring diagram of the heart is shown below in Figure 2. 
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Figure 2: Electrical wiring diagram of the heart (Wikimedia Commons Angelito7/CC BY-SA 3.0) 
The electrical activity of the heart can be detected by surface electrodes on the skin 
through the electrocardiogram (ECG) [8]. An example ECG with associated mechanical 
behavior of the heart, known as a Wiggers Diagram, is shown below in Figure 3. One of the 
most ubiquitous diagnostic tools in medicine, the ECG visualizes the heart’s electrical 
behavior. Typically, the ECG is divided into 3 distinct segments: the P wave, corresponding 
to atrial contraction; the QRS complex, corresponding to synchronized ventricular contraction 
and atrial repolarization; and the T wave, corresponding to synchronized ventricular 
repolarization [9]. 
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Figure 3: A Wiggers diagram, showing the cardiac cycle events occurring in the left ventricle  
(Wikimedia Commons xavax/CC BY-CA 2.5) 
The ECG is electromechanically coupled to the myocardium [10]. Under normal 
operating conditions, electrical signals on an ECG are followed by mechanical contraction 
after some electomechanical delay. Contraction is evidenced by cyclic changes in both pressure 
and volume within the heart, which are also illustrated above. The phonocardiogram, 
commonly measured with a stethoscope, monitors heart sounds associated with the closure 
valves within the heart.  
As the electrical wave-front propagates through the heart, the acting membrane 
potential of the cardiac conduction cells induce biochemical action, resulting in mechanical 
contraction of cardiac cells. The timing of the heart’s electrical system corresponds to the 
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chemically-based contraction of the entire organ. 
1.1.3. The Heart as a Chemical System 
Cells within the heart are divided into two classes: cardiomyocytes and pacemaker cells. 
These cells make up approximately 99% and 1% of all heart cells, respectively [11]. Cardiac 
cells are autorythmic, meaning they will spontaneously contract at a fixed rate without external 
stimulation if left unstimulated.  
Cardiac autorhythmicity results from a unique property of cardiac pacemaker cells 
where they, unlike other muscle or neuron cells, depolarize themselves. This behavior results 
from unique “leaky” sodium ion channels, which slowly permit sodium influx into the cell, 
passively decreasing transmembrane potential until voltage-gated calcium channels open and 
fully depolarize the cell. An example of the three-stage pacemaker cell depolarization process 
is shown below in Figure 4. 
 
Figure 4: Cardiac pacemaker cell membrane potential (Wikimedia Commons OpenStax College/CC BY-SA 3.0) 
Cardiac pacemaker cells, and in particular those located in the SA node, are responsible 
for the rhythmic stimulation and resulting contraction of the myocardium. Pacemaker cells 
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stimulate the remaining cardiomyocytes by transmitting the self-generated transmembrane 
potential through the rest of the organ, opening voltage-gated ion channels that affect internal 
cellular organelles. An example of the cardiomyocyte membrane potential is shown below in 
Figure 5. 
 
Figure 5: Cardiomyocyte cell membrane potential (Wikimedia Commons OpenStax College/CC BY-SA 3.0) 
The opening of calcium ion channels by the pacemaker potential induces a chemical 
change within the myofibril, a specialized organelle structure present in most muscle cells 
throughout the body. Myofibrils contain long chains of sarcomeres, which, as the fundamental 
contractile unit muscle, contract in the presence of calcium ions through a complex 
biochemical cascade. When coupled with thousands of other cardiomyocytes, this small effect 
in a single cell results in the macroscopic contraction dynamics of the heart [12]. 
The mechanical, electrical, and chemical subsystem of cardiac function completely 
characterize the heart’s behavior. Each connected subsystem is dependent on the other two 
for metabolic support; therefore, any failure within one system will cause fault in the other 
two. When the whole organ begins to fail in this way, cardiac dysrhythmia results. 
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1.2. Cardiac Dysrhythmia  
A cardiac dysrhythmia, or arrhythmia, describes any group of conditions where 
electrical activity of the heart is either too slow or too fast but that either ways results in a non-
optimal supply of blood to the body [13]. Cardiac dysrhythmias are typically classified as either 
tachycardia or bradycardia depending on the nature of the electrical failure within the heart. 
1.2.1. Tachycardia 
Tachycardia is a condition of high resting heart rate or irregular periods of high 
ventricular rate (HVR) [14]. A patient experiencing tachycardia is at risk for ventricular 
fibrillation (VF), an often fatal event during which the heart loses any sense of synchrony and 
ceases to effectively pump blood through the body. The heart may be resuscitated by a large 
voltage pulse delivered either internally or externally by a defibrillator [15]. To defibrillate a 
heart, a device, either external to or internal to the patient, generates a large voltage potential 
across the heart, inducing complete and instantaneous activation of myocardial voltage-gated 
ion channels. Following a complete reversion, leaky ion channels reestablish natural intrinsic 
rate. Although painful, a powerful shock delivered in time is often enough to terminate the 
fibrillation episode and resuscitate the patient.  
1.2.2. Bradycardia 
Unlike tachycardia, bradycardia is characterized by an abnormally slow resting heart 
rate typically below 60 beats per minute [16]. Greater duration between beats results in a 
decreased cardiac output, which could result in feelings of faintness, dizziness, or tiredness. 
Surface ECG recordings of bradycardia appear similar to a healthy ECG except for greater 
duration in the T-P interval  
 
10 
Possible causes and available treatment options for cardiac dysrhythmia are diverse. 
One common treatment option available to patients is the implantation of an artificial cardiac 
pacemaker. An artificial cardiac pacemaker is an implantable device designed to improve the 
electrical stimulation and timing of the heart by interfacing directly with myocardial tissue. A 
pacemaker stimulates the heart without need for the natural electrical control system, thereby 
providing a reliable means of maintaining sufficient contraction dynamics to fulfill metabolic 
demand. 
1.3. The Artificial Cardiac Pacemaker 
 An artificial cardiac pacemaker is an implantable medical device designed to alleviate 
symptoms associated with cardiac dysrhythmia by interfacing with the heart’s natural electrical 
conduction system, permitting the device to sense intrinsic electrical activity and to administer 
artificial electrical pacing pulses as needed. Bradycardia can be treated by a typical pacemaker 
capable of supplying appropriately timed current pulses at a healthy rate.  
A functional pacemaker is composed of two components: the can and the lead. The 
can is a titanium-encased module containing circuitry, battery, and, in the case of defibrillators, 
a large charge-storing capacitor. The lead is a long, flexible, insulated wire that connects the 
can to the heart tissue. Because pacemaker cans are large, they are typically implanted in a 
pocket under the skin somewhere superficial to the pectoral muscle. While pacemaker 
technology has been available for several decades, recent developments may revolutionize 
device design through miniaturization of the pacemaker can such that the entire device may 
be implanted directly in the heart without necessitating a lead.  
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1.3.1. Injectable Leadless Pacemaker 
Pacemaker technology developments have been principally focused on miniaturizing 
and improving device longevity. Recent technological advancements in battery storage and 
hardware miniaturization equip researchers with the possibility of removing the pacemaker 
lead from the system and collapsing the entire design into a device small enough to 
permanently reside within the right ventricle. Ideally, a leadless pacemaker would deliver 
electric charge near the apex, or bottom tip, of the right ventricle to promote even 
depolarization of cardiac tissue across both the right and left ventricles.  
Breaking away from nearly 50 years of pacemaker design precedent, removing the 
pacing lead from the design promises to absolve the device of a significant weakness and 
promote greater patient well-being [17]. Patients who require an artificial cardiac pacemaker 
often require long-term cardiac output monitoring. Therefore, an artificial cardiac pacemaker 
capable of estimating cardiac output is desired. 
1.4. Cardiac Output Estimation 
Physicians have many options to estimate and monitor a patient’s cardiac output. 
However, current methods require invasive catheterization, bulky external machinery, and/or 
highly trained medical specialists. Typical applications for cardiac output monitoring are 
divided into two classes: continuous and discrete monitoring, differentiated by the rate at 
which cardiac output values are reported. The following sections describe a few modern best 
practices commonly used to assess patient cardiac output.  
1.4.1. Echocardiography 
Echocardiography estimates cardiac output, stroke volume, and heart geometry 
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through 2-D and 3-D Doppler shift analysis to produce images of the heart. While effective, 
echocardiography requires both expensive machinery and a trained echocardiologist to operate 
effectively, as determined by the American Society of Echocardiography. Although widely 
recognized as a gold standard of continuous cardiac output monitoring, costs associated with 
echocardiography can be prohibitively high, routinely costing up to $2000 per session, often 
rendering use of echocardiography infeasible for use in developing nations1 [18]. 
1.4.2. PiCCO Thermodilution 
Pulse index Continuous Cardiac Output (PiCCO) monitoring leverages 
thermodilution principles to assess changes in rate of blood flow through the heart. PiCCO 
requires a thermistor and pressure catheter placed in or near the femoral artery to measure 
continuous changes in arterial pulse pressure [19], making it a more invasive solution than 
other less-invasive options. Pulse pressure contours is calibrated through cold saline bolus 
injections where the rate at which the cold saline dilutes is dependent on the amount of blood 
flowing through the heart.   
1.4.3. Direct Fick Method 
The Direct Fick Method leverages assumptions made by the Fick Principle that relates 
cardiac output to the rate of gas exchange in systemic tissue [20].  Because the Direct Fick 
Method requires drawing blood and gas content analysis, cardiac output estimations take place 
at long intervals, which makes the Direct Fick Method a poor choice for continuous cardiac 
output monitoring. 
                                                 
 
1 Or by hungry graduate students. 
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1.4.4. Impedance Cardiography 
Impedance cardiography (ICG) measures transthoracic impedance to assess 
estimations of stroke volume, cardiac output, and vascular resistance [21]. ICG requires two 
pairs of external transcutaneous leads; the first pair transmits a sinusoidal current through the 
thoracic cavity while the second pair measures the resultant voltage. Current is typically 
injected at 100 kHz and 4 mA to achieve optimal signal propagation without inducing cellular 
contraction [22]. The measured voltage is dependent on thoracic impedance. As the heart 
transfers fluid through the great vessels, thoracic impedance changes throughout the cardiac 
cycle.   
The electrical impedance between two leads is denoted with the letter Z. Ventricular 
ejection time (VET) is the period during when both pulmonary and aortic heart valves are 
open and blood is leaving the heart. Stroke volume is estimated with the intracardiac 
impedance waveform by the following equation. 
 𝑆𝑡𝑟𝑜𝑘𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 ∝  ∫
𝑑𝑍
𝑑𝑡
𝑉𝐸𝑇
  
By integrating the rate at which impedance changes during the cardiac cycle, a stroke 
volume index measurement is made. The reliability of impedance cardiography has been 
subject to debate, particularly when measuring low cardiac output [23]. Challenges associated 
with variable body types, placement of intracardiac shunts, or valvular regurgitation contribute 
to measurement distortion. However, impedance cardiography benefits from high 
reproducibility and an ability to resolve small changes in cardiac output on a frequent and on-
going basis making it a desirable, though challenged, method of cardiac output monitoring. 
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1.5. Contributions of the Author 
The purpose of this thesis is to introduce a novel means of monitoring changes in 
cardiac output. Like impedance cardiography, the proposed method illustrated in this thesis 
applies an alternating signal across the thorax; however, unlike traditional impedance 
cardiography where the impedance signal is measured from the surface of the skin, the 
proposed method monitors changes in sensed voltage from directly within the heart itself. 
This method may provide a more reliable measurement of stroke volume because it may not 
be as sensitive to other thoracic volume conductors, such as the great vessels or lungs, which 
may contribute to measurement distortion expected in traditional impedance cardiography. 
To process the intracardiac impedance signal and estimate changes in cardiac output, a novel 
algorithm has been developed. 
To illustrate the feasibility of the proposed method, the following steps were taken. 
First, a mathematical model of the heart was developed to predict expected changes observed 
from an intracardiac device located in the heart. Second, a mechanical simulator, designed and 
built to replicate expected changes in intracardiac impedance, was used to test and improve 
the preliminary algorithm prototype. Lastly, the method and algorithm were validated in a 
controlled large animal study. Results obtained from these studies, a discussion of their 
implications, conclusions drawn from this work, and potential future avenues of investigation 
are provided.  
1.5.1. Thesis Organization 
This thesis is organized into seven chapters. This first chapter has provided an 
introductory review of cardiac physiology, artificial cardiac pacemaker technology, and current 
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best practices of monitoring cardiac output. The second chapter describes the hardware 
system employed throughout this thesis, including a prototype implantable device, delivery 
tools, and implantation procedure. The third chapter describes a novel algorithm designed to 
monitor changes in cardiac output. The fourth chapter introduces a mechanical simulator 
designed and built to replicate cardiac dynamics expected within a living subject used to 
demonstrate feasibility of the algorithm described in chapter three. The fifth chapter discusses 
results obtained from the simulator and a brief discussion of how the results contribute to 
system validation. The sixth chapter discusses results obtained from an in vivo animal study 
and provides a discussion of both the value and limitations of the results. Lastly, the seventh 
and final chapter summarizes conclusions drawn from this work and provides 
recommendations for further avenues of research.  
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2. System Design 
The following chapter describes the system employed in this thesis to monitor changes 
in cardiac output. This chapter discusses the prototype intracardiac device, the requisite 
delivery tools, and the clinical procedures for delivering a mechanical prototype into the heart. 
These components were developed by Micro Systems Engineering, Inc. and were repurposed 
by the author for this investigation.  
2.1. Epoxy iLP Prototype 
In exploring leadless pacemaker performance, injectable leadless pacemaker (iLP) 
device prototypes were developed. The mechanical size and distance between electrodes of 
the epoxy device were analogous to the size and shape of a fully functional iLP device. This 
surrogate device does not contain any embedded hardware and was developed to record data 
from outside of the heart. The prototype device is composed of two electrodes: one at the rear 
of the device (the hitch) and one at the screw, which anchors the device into the myocardium. 
The two electrodes are separated by a fixed distance of 35 mm. The body of the device is 
molded from Loctite M-31CL Hysol, a medical-grade and non-conductive epoxy. The two 
electrodes are connected to drawn-filled tube (DFT) wires, connected to the iLP electrodes at 
one end and an industry standard IS-1 pacemaker lead connector on the other. When 
implanted, the DFT wires travel from the device out of the body where the IS-1 connector 
remains available for data collection. A simple diagram of the device is shown below in Figure 
6 illustrating how each of the iLP electrodes is connected to an external IS-1 connector.  
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Figure 6: Diagram of iLP and connecting terminal 
A photograph of the epoxy iLP prototype device is shown below in Figure 7. Both 
screw and hitch electrodes, as well as the white steroid-eluting collar around the screw, are 
visible. The steroid, Dexamethasone, is slowly released from the collar during chronic studies 
to suppress the foreign body immune response and to reduce scarring of the heart wall. The 
photograph also shows a titanium bar along the side of the device. Because titanium is 
radiopaque, the bars are clearly seen on x-ray and allow the implanting surgeon to monitor 
how many turns are used to screw the device into place. 
 
Figure 7: Epoxy iLP prototype device 
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2.2. Delivery Tool 
The prototype intracardiac device requires special tooling to navigate and fixate the 
device into the heart. Operated by a single surgeon, the delivery tool pinches onto the hitch 
of the device, steers the device into place, and applies torque to screw the device into the 
myocardium. Once the device is in place, the delivery tool disconnects from the wired 
prototype device and is extracted from the body without disrupting or applying tension to the 
DFT wires, leaving the iLP fixated securely near the apex of the right ventricle. 
2.3. Implantation Procedure 
The following describes the clinical procedure to implant an iLP into the right ventricle 
of an animal model. First, an incision is made at the site of the right external jugular vein in 
the neck. The vein is isolated and ligated distally from the heart. A guidewire is inserted into 
the jugular vein through a transvascular needle. Under fluoroscopic X-ray, the guidewire is 
navigated to the apex of the heart. Premature ventricular contractions (PVCs) seen on a surface 
ECG amplifier confirm that the guidewire is in the heart. Monitoring a surface ECG for PVCs 
is a practical means of determining whether a device is within the heart. Myocardial tissue is 
extremely sensitive to mechanical disturbance due to the sensitive nature of the leaky calcium 
ion channels.2  
Next, a tissue dilator and sheath are passed over the guidewire, through the SVC, and 
into the heart. Fluoroscopy provides assurance that the tools are delivered to the heart and do 
                                                 
 
2 As an aside, during open-heart surgeries requiring cessation of cardiac contraction, the heart is completely 
arrested both pharmacologically and by packing the chest cavity with ice. When the heart is ready for reactivation, 
the ice is removed. Once the heart is warm, the surgeon needs only to flick the heart with a finger to activate the 
ion channels and jump-start the cardiac cycle. 
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not penetrate the tissue. The dilator is designed to widen the vein prior to device delivery and 
reduce the likelihood of tearing the vessel as the tool passes through. The sheath is a stiff, 
thin-walled tube placed around the dilator. Once the dilator is in the heart, both the dilator 
and guide wire are removed through the sheath, leaving just the hollow sheath behind, 
providing an isolated and unimpeded pathway from outside of the body directly into the right 
ventricle.  
The delivery tool and connected iLP are together passed through the sheath and into 
the right ventricle where, under fluoroscopy, the iLP is screwed into the apex of the heart. 
Once the iLP is fixated into the tissue, the delivery tool releases the device and is removed out 
through the sheath. Once removed, the sheath is removed from the body, leaving just the iLP 
behind. The jugular vein is tied off around the DFT wires to reduce blood effusion, leaving 
the IS-1 connector exposed to provide a direct electrical connection to the heart’s interior. 
2.4. AC Signal Generation 
As in traditional impedance cardiography, monitoring changes in cardiac output from 
an intracardiac device requires a transthoracic signal to drive intracardiac impedance 
measurement at a given frequency. An isolated alternating current generator injects current 
through a pair of surface silver chloride ECG patches across the thorax. The patches are placed 
along the same vector as the implanted iLP device and separated by a distance twice the 
device’s depth from the skin surface, marked with grey circles on the diagram below in Figure 
8.  
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Figure 8: Approximate locations of signal injection electrodes indicated by grey circles. Grey circles indicate 
approximate current injection electrodes. iLP shown to scale 
 
The objective of this thesis is to leverage the tools and resources presented in this 
chapter to acquire meaningful information regarding intracardiac dynamics. The following 
chapter describes an algorithm designed to monitor changes in intracardiac impedance to 
assess changes in cardiac stroke volume. 
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3. Algorithm Design 
Measuring changes in cardiac output requires an algorithm to derive and process the 
intracardiac impedance signal. To best design an algorithm for this task, a foundational 
understanding of the biophysical principles involved in this problem is desired. The following 
section describes the biophysical theory to explain how variation in intracardiac impedance is 
related to stroke volume.  
3.1. Theoretical Basis 
The iLP is implanted within the right ventricle. When the heart is relaxed, the device 
is surrounded by blood. As the heart contracts around the device, blood is ejected and the 
heart wall presses against the implanted iLP device, as evidenced by scar tissue formation on 
the heart wall following chronic implantation.  
Blood and myocardium together provide current paths across the iLP device. As the 
heart contracts, the relative volumes of tissue and blood within the vicinity of the iLP change. 
As more-conductive blood is replaced by less-conductive myocardium during contraction, the 
impedance magnitude across the two iLP electrodes increases, increasing the sensed voltage 
amplitude across the iLP in accordance with Ohm’s Law. 
The characteristic electromechanical coupling between heart contraction and 
intracardiac impedance has been thoroughly established [24]. An example of 
electromechanical coupling derived from this investigation is shown in Figure 9. The 
intracardiac impedance increases after the QRS complex, indicating that the mechanical 
contraction expected after a QRS wave increases the impedance within the heart.  
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Figure 9: Single cardiac cycle visualized both with the intracardiac impedance curve and the IEGM 
The time delay between the QRS wave and impedance increase is the 
electromechanical delay between electrical stimulation, the biochemical reaction cascade, and 
resultant mechanical contraction. As expected, the intracardiac impedance rises during systole 
and decreases during diastole. Both impedance and intracardiac electrogram (IEGM) are 
derived from the same sample of raw data collected from an implanted iLP.  
The observation of sensed signal amplitude modulation discussed in the previous 
chapter provides evidence that an implanted iLP could theoretically extract information about 
intracardiac dynamics from the impedance signal driven by a high frequency voltage source, 
just as impedance cardiography monitors changes in thoracic impedance to estimate cardiac 
parameters.  
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3.2. Mathematical Model of Expected Impedance Changes 
To better predict the expected range of impedance change throughout the cardiac 
cycle across an implanted iLP, a mathematical model of time-varying cardiac impedance was 
developed. In this model, the heart is treated as a pair of nested cylinders. The outer cylinder 
represents the myocardium and the solid inner cylinder represents blood. Figure 10 shows the 
two cylinders surrounding a solid iLP model embedded within them. As the heart contracts, 
the volume of blood is reduced as blood is ejected out of the chamber. This physical behavior 
is modelled as a simultaneous contraction and thickening of the myocardium such that the 
cross-sectional area of the heart wall remains constant. The physical embodiment of the 
mathematical model is shown below in Figure 10. 
 
Figure 10: Simplified model of the right ventricle used to mathematically predict expected impedance changes 
The specific geometric parameters of the physical model are derived from typical 
parameters associated with the human heart. The physical parameters used for this evaluation 
are tabulated below in Table 1. 
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Table 1: Parameters utilized in the nested cylinder mathematical model 
Diameter of iLP (mm): 7.0 
Length of iLP (mm): 35 
End Systolic Volume (mL): 50 
End Diastolic Volume (mL) [25]: 120 
Wall Thickness (mm) [26]: 4.0 
RV length (mm) [27]: 76 
Blood Resistivity (Ω/m): 1.36 
Myocardium Resistivity (Ω/cm): 206 
The physical geometry of the mathematical model is coupled with known electrical 
properties of human tissue to produce a simplified model of the right ventricle. 
3.2.1. Tissue Resistance and Reactance 
Human biological tissue is complex, consisting both of extracellular components, cells, 
and intracellular components. Modeling biological tissue is slightly more complex than typical 
electrical components as cell walls have been shown to act as biological capacitors, separating 
charged ions between in the inside and outside of an individual cell. Biological tissue is typically 
electrically modelled with both pure resistance elements and complex capacitance elements 
which accounts for both the purely resistive interstitial fluid between cells as well as the charge-
separating capacity of cellular walls [28]. Mathematically tissue modeling must consider both 
real and imaginary components of complex impedance.   
Electrical characteristics of myocardial tissue have been extensively investigated. 
Characterizing intracardiac dynamics requires understanding the complex nature of 
intracardiac impedance. Considering capacitance, the impedance of complex biological 
material includes an imaginary component and an associated phase angle to account for both 
the real resistance and imaginary reactance of tissue. According to recent studies, healthy 
myocardial tissue is characterized as having an impedance magnitude of 206 ± 40 Ω·cm and 
a phase angle of -8.8 ± 0.7º at 100 kHz, the frequency of AC signal injection [29]. Data 
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characterizing healthy myocardial tissue impedance at the frequency of carrier injection 
throughout the cardiac cycle was not found. However, because myocardial impedance is 
dominated by the real component of impedance, the mathematical model presented here 
assumes that the capacitance remains constant throughout the cardiac cycle and that 
impedance magnitude is dependent on the geometry of the myocardium.  
The resistance of a three dimensional material can be derived from Pouillet’s Law by 
relating the known electrical resistivity of a material and its geometry. Pouillet’s Law is shown 
in the equation below where 𝑅 is the net electrical resistance, 𝜌 is the material’s known 
electrical resistivity, 𝑙 is the length of the material, and 𝐴 is the material’s cross-sectional area. 
𝑅 =  𝜌
𝑙
𝐴
 
This model assumes that both the myocardium and the blood can be modeled as 
nested cylinders whose height and electrical resistivity remain constant while the cross-
sectional area changes throughout the cardiac cycle. Resistance is calculated between the two 
electrodes of an embedded iLP. This model only considers changes in real impedance of the 
heart. By treating the impedance magnitudes of blood and myocardium as parallel resistors, 
an equivalent resistance is determined. The impedance magnitude of both tissues and their 
equivalent resistance as a function of stroke volume are shown below in Figure 11.  
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Figure 11: Mathematical prediction of resistances for blood, myocardium, and their functional equivalent 
The above figure illustrates how the functional resistance across the iLP is expected to 
change over the course of the cardiac cycle. From the above data, a nominal stroke volume of 
70 ml would correspond to an increase in device resistance of approximately 221 ohms or a 
189% increase in resistance from end diastolic volume to end systolic volume.  
A simplified schematic of the body conductor model is shown below in Figure 12. As 
shown in the following schematic, an offset resistance associated with the path from the 
current injection to the iLP is expected. Additionally, alternative current paths exist away from 
the iLP. In a body, these could be any of the fluid-filled, more conductive great vessels such 
as the aorta, the superior vena cava, and the inferior vena cava capable of conducting current 
away from the heart. How significantly alternative current pathways affect the overall 
equivalent resistance of the body is difficult to predict and likely varies significantly between 
individuals. For the purpose of simplification, these variables are excluded from this model. 
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Figure 12: Model circuit diagram of the body where elements specific to the heart are circled in red 
As shown in the above diagram, the variable resistance of the two conducting mediums 
within the heart has a direct impact on the measured voltage across the iLP. However, the 
presence of alternative current pathways and the varying degrees that they shunt electrical 
current away from the iLP throughout the cardiac cycle are difficult, if not impossible, to 
predict or model accurately. Because these alternative current pathways are not accounted for 
in the nested cylinder model, it is reasonable to presume that the model overestimates the 
expected impedance change as the presence of alternative current pathways would lower the 
equivalent resistance of the whole body conductor and reduced sensed voltage amplitude at 
the iLP. 
3.3. The Z-Cardio Algorithm 
The algorithm designed to process the time-varying intracardiac impedance profile and 
provide a measurement of cardiac output was designed in MATLAB and is hereby referred to 
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Z-Cardio. The Z-Cardio algorithm is designed to monitor changes in systolic intracardiac 
impedance through the process detailed in the high-level flow diagram below in Figure 13. 
 
Figure 13: High-level flow diagram of the Z-Cardio algorithm 
The purpose of the algorithm is to process the measured voltage at an iLP to render 
meaningful clinical data pertaining to intracardiac dynamics. First, a device is implanted in the 
right ventricle. A pair of surface electrodes generates a high frequency voltage source across 
the thorax to drive the intracardiac impedance signal at a known frequency. Raw voltage data 
is collected from the two electrodes of the iLP from within the heart.  
Collected data is processed in two parallel paths. The first stage, shown in green above, 
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isolates the IEGM from the raw voltage signal by applying a low-pass filter to remove the 
high-frequency voltage source and other irrelevant physiological noise. The QRS is detected 
by a simple threshold-crossing criterion where a QRS marker is designated at the point where 
the IEGM first crosses a positive threshold value. The rate that the QRS is detected is the 
heart rate; the interval between two QRS events is the R-R interval, or the heart rate period. 
While heart rate could be derived from the intracardiac impedance curve, the heart’s electrical 
activity may be a more reliable means of estimating heart rate periodicity because it relies on 
less complex signal processing. 
The raw data is also processed to extract the envelope of the generated voltage source 
undergoing amplitude modulated throughout the cardiac cycle. As described previously, the 
cardiac cycle modulates the impedance across the iLP by alternating the relative ratio of blood 
and myocardium, each possessing unique conductivities. As the contracting heart changes 
impedance across the device, the measured voltage will change according to Ohm’s Law.  
The envelope detection process is colored yellow in the flow diagram above. First, a 
digital high pass filter removes any physiological electrical activity, isolating the voltage source 
and removing any DC offset from the raw voltage signal. The signal is full wave rectified and 
filtered with a low pass filter to produce a clean envelope signal, which represents the 
intracardiac impedance signal shown in yellow in the top plot of Figure 14 below.  
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Figure 14: Illustration of the Z-Cardio algorithm processing cascade. The top plot shows the raw data in black 
and the low-pass trend in yellow. The middle plot shows the differential of the yellow trace from the top plot, 
and highlights the positive portion (half-wave rectification) of the curve in red. The bottom plot shows the 
integral of the red curve shown in the middle plot for each beat.  
The voltage source envelope signal is differentiated with respect to time, referred to 
here as dZ/dt. The first time derivative describes how the rate of change in intracardiac 
impedance varies with time. Of specific interest is how the intracardiac impedance signal 
changes during systole, when the heart is contracting. Only during systole is blood ejected 
from the heart. Because the rate of intracardiac impedance change is positive during systole, 
only the positive portion of the dZ/dt curve is of interest, highlighted in the middle plot of 
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Figure 14. The time duration of each positive dZ/dt segment is the time when impedance is 
increasing and blood is being ejected, or the ventricular ejection time (VET). 
To estimate stroke volume, the area under each of the positive dZ/dt segments is 
integrated over the R-R interval for each beat. This stroke volume index is shown in the 
bottom plot of Figure 14. Notice how rhythmic fluctuations in the stroke volume index 
correspond to the respiration rate, known to have a significant impact on cardiac stroke 
volume [30]. As the diaphragm contracts downwards to inspire, thoracic pressure is reduced, 
increasing ventricular preload and increasing stroke volume.  
By the two processes described above, both heart rate and a stroke volume index can 
be estimated. Their product is a cardiac output index. This value is assumed to be correlated 
to a measured cardiac output, requiring the employment of a gold standard calibration metric 
for true cardiac output estimation.  
The injected signal is an alternating voltage signal at 100 kHz. The amplitude was 
adjusted such that the amplitude of the sensed signal at the implanted device was 
approximately 15 mV. The amplitude of the injected signal is adjusted to ensure that the 
amplitude of the sensed signal does not rail the input to the DAQ. A passive RC anti-aliasing 
filter was used at the input of the DAQ to attenuate frequencies above the Nyquist frequency. 
Because data was sampled continuously at 400 kHz, the Nyquist frequency is 200 kHz. To 
ensure that frequency spectra at and above the Nyquist frequency are sufficiently attenuated, 
the RC anti-aliasing low-pass filter was designed with a corner frequency at 160 kHz. A second 
high-pass RC filter was cascaded with the RC anti-aliasing low-pass filter to remove any DC 
offset of the signal detected by the implant. The corner frequency of the high-pass front-end 
filter is 1 Hz, sufficient to attenuate the DC component of the input signal yet low enough to 
 
32 
not substantially distort the desired electrical activity of the heart.  
In this design, the low-pass and high-pass filters are designed in MATLAB as second 
order Butterworth filters. Second order Butterworth filters are desirable because they exhibit 
zero ripple in the passband frequency range, have relatively steep roll-off of 40 dB/decade, 
and are easily implemented in analog circuitry. While analog filter realization is not a direct 
design requirement of this thesis, any effort to implement Z-Cardio into implantable hardware 
would benefit from translating the digital filters into analog filters on a printed circuit board 
to offload as much computation and battery power demand from the implant device as 
possible.  
The QRS wave detection block places markers over instances of a QRS wave in the 
IEGM. A simple amplitude threshold criterion determines the presence of a QRS wave. The 
programmed amplitude is dependent on the amplitude of the detected signal and is selected 
by the user to optimize detection consistency. 
Validation of the Z-Cardio algorithm requires a living model and in vivo 
experimentation protocol. To support justification for animal experimentation, illustrating that 
the Z-Cardio algorithm is capable of monitoring changes in stroke volume in a benchtop 
simulator is desired. A simulator designed to model expected impedance changes within an 
animal model used to assess the Z-Cardio algorithm was constructed. 
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4. Simulator Design Requirements and Verification  
To conform to both national and international regulations governing the medical 
device industry, validation of the Z-Cardio algorithm requires the use of large animal models 
in well-controlled, well-documented, and well-supported clinical studies. The use of animals 
in medical device testing, while necessary for ensuring the safety and well-being of the patient, 
should be minimized to reduce both financial costs and costs associated with animal sacrifice. 
While a simulator cannot completely replace the need for live animal study, a simulator can 
provide a valuable tool to validate the Z-Cardio algorithm concept and to validate the 
technology as much as possible prior to animal study. D.I.C.E., the Dynamic Intra-Cardiac 
Emulator, was designed and constructed to support early stage design validation. 
4.1. Design Requirements 
To provide a useful tool to validate the Z-Cardio algorithm, an intracardiac impedance 
simulator must fulfill each of the following design requirements. 
4.1.1. Low-Cost and Rapid-Development Design 
Establishing bench-top proof-of-concept as soon as possible more easily facilitates 
clinical study protocol planning. Constrained by a limited development budget, the simulator 
must be low-cost and should be designed and constructed in a reasonably short time frame. A 
simple and elegant design solution is desired. 
4.1.2. Controllable and Measurable Simulator Stroke Volume  
The purpose of the simulator is to facilitate development of an algorithm capable of 
monitoring changes in stroke volume. Therefore, any estimation made by the algorithm must 
be correlated to the true stroke volume of the simulator. To accommodate a range of stroke 
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volumes and to provide a standard for the Z-Cardio algorithm, the simulator’s stroke volume 
must be both controllable and measurable.  
4.1.3. Voltage Source Generation Across the iLP  
Measuring intracardiac impedance requires a driving source. In an animal or human 
subject, a high frequency voltage source is generated across surface patch electrodes. The 
simulator must accommodate a similar means of voltage generation such that the voltage is 
detectable by an iLP. 
4.1.4. Blood and Myocardial Tissue Emulation 
When the heart contracts, the composition of the tissue surrounding the iLP changes 
as the chamber ejects blood and contracts myocardial tissue. Because the iLP is located entirely 
within the heart, assuming that the local impedance profile is modulated primarily by the 
alternating ratio of both blood and myocardium within that chamber is reasonable.  
When the heart is in peak diastole, a large volume of conductive blood provides high-
conductivity pathways between the two iLP electrodes. By reducing the impedance magnitude 
across the device during diastole, the amplitude of an observed voltage driven by the voltage 
source would be lower, in accordance with Ohm’s Law. As the heart begins to contract, the 
muscular, less conductive heart wall approaches the device, effectively replacing the more-
conductive blood with less-conductive myocardium within the heart. At peak systole, when 
the heart is least filled with blood, the myocardium most completely surrounds the iLP, 
maximally impeding current flow between the iLP electrodes and thereby maximizing the 
sensed voltage across the iLP. The D.I.C.E. simulator must therefore model the conductivities 
of both blood and myocardium and control how the relative ratio of each of the tissues 
changes around an iLP during contraction. 
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4.1.5. Realistic Impedance Modulation 
The purpose of the simulator is to recreate an impedance profile similar to what would 
be expected from within a living subject’s heart. While an exact replication of intracardiac 
impedance is desired, the simulator must at the very least increase and decrease impedance 
magnitude during systole and diastole, respectively, to be considered an acceptable simulation. 
As previously discussed during mathematical model description, complex tissue impedance is 
composed of both real resistance and imaginary reactance components. However, studies 
suggest that the impedance magnitude of myocardial tissue is dominated by the purely resistive 
component of impedance. Because the Z-Cardio algorithm is designed to monitor changes in 
amplitude and not changes in signal phase, only impedance magnitude is calibrated for the 
purpose of this simulation. 
4.2. D.I.C.E. Design 
D.I.C.E. was designed to simulate the natural rhythmicity of intracardiac impedance 
expected within a living subject’s heart during cardiac contraction. The design of the simulator 
is described by two major design components. The emulated tissue design describes how 
appropriate tissue analogs were created to simulate the electrical conductivity of blood and 
myocardial tissue. The mechanical design describes the physical simulator, how it incorporates 
the emulated tissue, and the means to control simulated stroke volume.  
4.2.1. Emulated Tissue Design 
The D.I.C.E. bench-top simulator was designed to modulate impedance across the 
iLP by controlling the relative ratio of blood and myocardium surrounding the iLP device 
during contraction. Because both blood and myocardium are organic tissues, non-living 
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alternatives were developed to eliminate the need for tissue acquisition and preservation. To 
ensure that alternative analogs for blood and myocardium were appropriate for the design 
purpose, each alternative was calibrated to known electrical properties of their respective 
natural tissue. However, artificial analogs lack the cell walls present in biological tissue that 
introduce capacitive reactance. To simplify the design of emulated tissue, artificial tissue 
impedance magnitude is calibrated independent of resistance and capacitive effects. We 
assume impedance of the tissue analog is dominated by pure resistance. 
Saline solution is marketed as a tissue analog. While saline solution is available for 
purchase, creating original saline solutions provides greater control over electrical 
conductivity, essential when calibrating saline to known human tissue properties.  Phosphate-
buffered saline (PBS) tablets were chosen because they are cheap, readily available, and provide 
greater control over saline concentration and electrical conductivity than off-the-shelf saline 
solutions. Mixed with distilled water, PBS tablets dissolve to produce an isotonic salt saline 
solution whose osmotic concentration, ion concentration, and pH match those of human 
tissue. Controlling the concentration of PBS controls the ionic concentration and electrical 
conductivity of each solution.  
Both blood and myocardial solutions were produced by measuring solution impedance 
magnitude at a known frequency while mixing PBS with distilled water until target values were 
reached. Figure 15 plots the target conductivities of blood and myocardium saline solutions at 
the nominal frequency band of voltage generation [31]. 
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Figure 15: Resistivity of blood and myocardium over the nominal voltage generation frequency band 
Both blood and myocardial analogs were incorporated into a mechanical device that 
prevented the two solutions from mixing while mimicking the contraction dynamics of a 
natural heart. 
4.2.2. Mechanical Design 
A mechanical design requires both the artificial blood and myocardium calibrated 
saline solutions be separated to prevent mixing and compromising their unique conductivities. 
The interface chosen between the two solutions is a silicone bladder with a wall thickness of 
5 mm and an internal volume of 100 mL, approximately the volume of a healthy right ventricle 
[32]. Silicone is a good candidate for a solution interface because it is low-cost, non-porous, 
flexible, and retains its shape after plastic deformation. 
The top outflow tract of the silicone bladder was connected to a graduated cylinder. 
The cylinder is incorporated to provide the user a convenient means to measure the volume 
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of fluid ejected from the silicone bladder. The difference in meniscus height within the cylinder 
during contraction is the system stroke volume.  
The blood-filled silicone bladder was submerged into a container of myocardium 
saline. The container was built from Plexiglas, a light-weight, transparent, and inexpensive 
plastic that is easily made water-tight. The draft design drawing of the Plexiglas housing is 
found in Appendix A: D.I.C.E. Design Drawing. The housing was designed with size and 
weight in mind, thereby permitting portability as necessary.  
The simulator must consistently compress the silicone bladder in a manner similar to 
how the right ventricle deforms during cardiac contraction. A uniform deformation within the 
simulator requires a uniform positive pressure increase of the myocardium saline. An increase 
in pressure collapses the silicone bulb and ejects blood saline up the graduated cylinder. To 
induce a positive pressure increase in the myocardium saline, a compressible hand-pump was 
connected to the side of the Plexiglas housing and filled with myocardial saline. The hand 
pump has an internal volume of 150 mL, slightly greater than the volume of a healthy right 
ventricle, necessary to replicate a stroke volume range between 55 and 100 ml, or the nominal 
stroke volume range expected within a healthy human heart [33]. When the hand-pump is 
compressed, the resulting pressure deforms the silicone bladder and ejects blood saline up the 
graduated cylinder, ensuring that the simulator stroke volume is both controllable and 
measureable. 
In a typical clinical setting, the high frequency voltage potential would be generated 
across a pair of surface patch electrodes located on the subject’s skin. Because Plexiglas is a 
poor conductor, a voltage potential generated from outside of the Plexiglas would experience 
its greatest drop across the Plexiglas wall, making the signal more difficult to detect at an iLP. 
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Instead of generating the voltage from outside the Plexiglas, two wire electrodes were 
suspended in the myocardium solution through which the high frequency voltage was 
generated, thereby ensuring that the high frequency signal is more easily detected by the iLP. 
4.3. D.I.C.E. Prototype 
Following the proposed design plan described above, a functional prototype of the 
D.I.C.E. simulator was constructed. A photograph of the experimental simulator and its 
associated hardware, including a function generator and a laptop running MATLAB, is shown 
below in Figure 16.  
 
Figure 16: D.I.C.E. and associated hardware 
Two close-up photographs of the D.I.C.E. simulator are shown below in Figure 17. 
Note the red silicone bladder filled with blood saline, the graduated cylinder from where stroke 
volume is measured, and the wires hanging out the top of the graduated cylinder that connect 
to an iLP embedded within the silicone bladder. The red and black wires through the top of 
the Plexiglas housing are used for voltage generation. The compressible hand-pump is 
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connected to the simulator by the clear tubing shown near the bottom of each photograph. 
The black compressible hand-pump is seen more clearly in the preceding photograph above 
in Figure 16.  
       
Figure 17: Close-up photographs of the D.I.C.E. simulator 
The contraction dynamics of the simulator are illustrated in the series of three 
photographs shown below in Figure 18. The photographs depict the progressive deformation 
of the silicone bulb during the course of contraction within the simulator. The meniscus within 
the graduated cylinder rises as the silicone bulb deforms, indicated below with black arrows. 
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Figure 18: Simulator contraction dynamics of increasing stroke volumes indicated in the graduated cylinder by 
black arrows 
4.4. Design Verification 
The prototype D.I.C.E. simulator was designed to fulfill the requisite design 
requirements. The design was planned and executed in a reasonable time frame and within a 
limited budget, thereby fulfilling the first design requirement. The design allows for a 
controllable and measurable stroke volume through the use of a hand-pump and a graduated 
cylinder, thereby fulfilling the second design requirement. A high frequency voltage source can 
be generated across a pair of electrodes submerged within the simulator such that the signal is 
detectable by an iLP, thereby fulfilling the third design requirement. Two uniquely calibrated 
saline solutions designed to match known electrical conductivity constants of human tissues 
were developed and incorporated into the D.I.C.E. design, thereby fulfilling the fourth design 
requirement.  
To verify that the D.I.C.E. simulator fulfills the fifth design requirement, the following 
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assessment sought to quantify impedance change across an iLP within the simulator as a 
function of the simulator stroke volume. The D.I.C.E. system’s stroke volume was measured 
by observing changes in meniscus height within the graduated cylinder. The impedance across 
the iLP was measured by an impedance meter calibrated to the frequency of voltage 
generation. The linear model associating simulator stroke volume and impedance across the 
iLP is shown below in Figure 19. 
 
Figure 19: Regression analysis between D.I.C.E. stroke volume and impedance across the iLP 
The above figure illustrates a linear relationship between D.I.C.E. stroke volume and 
observed changes in impedance across an embedded iLP device. The linear relationship 
between impedance (ohms) and stroke volume (mL) is 0.5285 ohms per milliliter. These results 
contrasts with the mathematical expectation as predicted by the nested cylinder model. The 
expected change in impedance associated with a 70 ml stroke volume according to the 
mathematical model was 220 Ω whereas in the D.I.C.E. simulator the change was 
y = 0.5285x + 707.15
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approximately 22 Ω. This significant deviation could result from poorly mathematically 
modeling alternative current pathways throughout the body during the cardiac cycle or from 
other physical behavior not accounted for by the mathematical model that nevertheless 
manifest within the D.I.C.E. simulator. Despite less significant changes in impedance across 
the iLP device than expected, the impedance profile nevertheless reflects reasonable 
expectations of a live animal model, thereby fulfilling the fifth and final design requirement.  
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5. Simulator Analysis, Results, and Discussion 
Following the assembly of the prototype D.I.C.E. simulator, performance of the Z-
Cardio algorithm was evaluated by comparing the measured simulator stroke volume to the 
Z-Cardio stroke volume estimate that is derived from the impedance profile of the simulator. 
In this analysis, the Z-Cardio algorithm needs only measure changes in stroke volume instead 
of cardiac output as monitoring heart rate from within a living heart is a trivial challenge. 
5.1. Algorithm Performance and Stroke Volume Comparison 
The following assessment of the D.I.C.E. simulator sought to evaluate how the stroke 
volume estimation made by the Z-Cardio algorithm compared to the stroke volume measured 
from the simulator. The following study sampled data continuously from the embedded iLP 
device while the D.I.C.E. simulator contracted across a range of physiologically appropriate 
stroke volumes. Figure 20 illustrates the impedance profile during five D.I.C.E. contractions 
at five stroke volumes, stepping up in stroke volume amplitude every five contractions. The 
first component of the algorithm that isolates the intracardiac impedance signal from the high 
frequency voltage signal envelope is applied to the raw data. 
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Figure 20: Filtered intracardiac impedance signal collected from an iLP embedded in the D.I.C.E. 
The above figure provides preliminary evidence that the simulator is modulating 
impedance across an iLP device with respect to the system stroke volume as evidenced by an 
increasing in peak signal amplitude corresponding to increasing system stroke volume. In 
Figure 21 below, the remainder of the Z-Cardio algorithm is applied to the filtered input 
stream shown above to monitor changes in simulator stroke volume. The top trace scales the 
filtered input signal as shown previously in Figure 20. The middle trace plots the positive 
differential of the input signal. According to the underlying theory of the Z-Cardio algorithm, 
the middle trace is the rate of contraction during systole. The bottom trace plots the stroke 
volume estimations made by the Z-Cardio algorithm for each stroke of the simulator. 
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Figure 21: Illustration of the Z-Cardio algorithm signal processing cascade applied to simulated data 
The three traces above in Figure 21 illustrate the relevant signal processing steps of 
the Z-Cardio algorithm taken to produce a stroke volume estimate. The bottom plot is the Z-
Cardio stroke volume index, a measurement expected to be proportional to the system stroke 
volume. The relationship between the Z-Cardio stroke volume indices and the measured 
D.I.C.E. stroke volume is shown below in Figure 22. To evaluate how averaging several 
samples taken at the same simulated stroke volume improve the performance of the Z-Cardio 
algorithm, measurements were made several times at discrete intervals.  
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Figure 22: Linear fit between Z-Cardio stroke volume indices and the measured stroke volume of the D.I.C.E. 
system. The blue dots are individual measurements while the red dots are the average for the measurements 
made for each stroke volume 
5.2. Weaknesses  
Despite a relatively strong correlation amongst averaged samples (R2 = 0.8321), 
significant variation exists between individual measurements for a common system stroke 
volume. Although the fit between all individual samples is poor (R2 = 0.3488), the fit between 
the average values of each stroke volume suggests a significantly stronger correlation (R2 = 
0.8321). This is an acceptable limitation because in practice a reported stroke volume 
estimation by Z-Cardio would be made over several contractions and not rely exclusively on 
individual measurements. Variation amongst individual samples may result from several 
factors.  
First, the simulator does not control for time-varying physical dynamics, rate of 
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compression, or reproducibility of impulse contraction. These features are dependent upon 
the human hand operating the simulator. Other factors contributing to variation could result 
from the geometric orientation of the device within the silicone bulb during contraction. 
Although it has been shown that the impedance across the device does change with stroke 
volume, the orientation of the device relative to the high frequency voltage generation vector 
would modulate the amplitude of the sensed signal. This weakness manifests itself within living 
subjects as well, making it a fundamental weakness of this technology. However, effects 
associated with cyclic vector reorientation of the iLP could be mitigated by ensuring that the 
vector of voltage generation is as near to the mean iLP vector as possible.  
Despite various shortcoming, results obtained from the Dynamic Intra-Cardiac 
Emulator suggest that the Z-Cardio algorithm possesses some capacity to estimate changes in 
stroke volume from the intracardiac impedance signal. The simulator described in this chapter 
has supported demonstrating the feasibility of this technology prior to engaging in animal 
study. 
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6. Animal Study Design, Results, and Discussion 
Investigations focused on the features and functionality of non-approved, Class-III 
medical devices are not always possible in humans without first establishing their safety and 
efficacy in an animal model. Extensive investigations into features and functionality using in 
vitro and heart model simulators reduce and refine the experimental model and prototypes. 
Yet, present models do not completely simulate the in vivo cardiac function when integrated 
with the circulatory system and autonomic nervous system. The complexity of biological 
systems surpasses that of most bench-top simulations designed to assess a technology’s 
performance. 
Swine (Sus scrofa domestica) are an established animal model for cardiovascular device 
research [34]. The anatomical and physiological similarity between the human cardiovascular 
system and that of a swine allows the swine to accommodate necessary instrumentation while 
providing accurate and thorough evaluations of medical devices prior to human implantation.  
Medical technology requires extensive animal evaluation before a regulatory body 
cedes permission to market and sell a technology to a human end user. A study protocol was 
developed to collect data from a living swine subject to demonstrate the feasibility of the Z-
Cardio system. The study protocol was approved by the Institutional Review Boards (IRBs) 
of both Micro Systems Engineering, Inc. and Legacy Research Institute in Portland, OR. The 
study protocol pertinent to the Z-Cardio algorithm is available in Appendix B: In Vivo Data 
Collection Study Protocol.  
6.1. Outline of Study Protocol 
The purpose of the animal study was to evaluate whether the Z-Cardio algorithm is 
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capable of monitoring changes in cardiac output with respect to a gold standard. A more 
detailed copy of the study procedures is found in Appendix C: Z-Cardio Data Collection 
Procedure. The following study procedures outline the steps taken within the laboratory. 
1. Prepare a single swine subject for surgery, monitor vitals, induce anesthesia 
2. Implant a wired iLP epoxy prototype device into the right ventricle 
3. Apply surface ECG patches onto the skin for high frequency voltage generation 
4. Connect a DAQ to the exposed terminal of the wired iLP 
5. Insert catheters, initiate cardiac output monitoring via thermodilution (PiCCO) 
6. Begin high frequency voltage generation 
7. Begin recording data from the iLP through the DAQ 
8. Begin streaming data from PiCCO to a USB thumb drive 
9. Wait several minutes to record a baseline measurement 
10. Inject a single dose of a positive inotropic pharmacological agent 
11. Wait several minutes for cardiac output to spike and return to near baseline 
12. Inject a second dose of a positive inotropic pharmacological agent 
13. Wait several minutes for cardiac output to spike and return to near baseline  
14. Inject a third dose of a positive inotropic pharmacological agent 
15. Wait several minutes for cardiac output to spike and return to near baseline 
16. Inject a dose of a negative inotropic pharmacological agent 
17. Wait several minutes for negative inotrope to take affect 
18. After several minutes, euthanize the subject per facility protocol 
19. Stop recording data from both DAQ and thermodilution monitor 
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6.1.1. Gold Standard  
The purpose of this study was to evaluate whether the Z-Cardio algorithm is capable 
of accurately monitoring changes in cardiac output with reference to a known gold standard 
in a living subject. The gold standard chosen to employ in this experiment was a PiCCO (Pulse 
Index Continuous Cardiac Output) thermodilution cardiac output monitoring system. PiCCO 
was chosen because the hardware and requisite catheters were readily available, required less 
set-up time than other systems, provided continuous monitoring and streaming capabilities, 
and did not require trained professionals to operate effectively.  
PiCCO monitoring integrates a wide array of both static and dynamic hemodynamic 
data through a combination of trans-cardiopulmonary thermodilution and pulse contour 
analysis [35]. The PiCCO monitor requires both venous and arterial catheters placed into the 
body of the subject. Iced saline is delivered through a venous catheter placed near or within 
the right atrium. A thermistor catheter placed within the femoral artery monitors changes in 
blood temperature as the iced saline bolus passes through the vascular system. PiCCO derives 
an estimation of cardiac output from the contour curve of the temperature change.  
While PiCCO reports true values of stroke volume and cardiac output, Z-Cardio 
reports indices of both stroke volume and cardiac output. This is an acceptable limitation 
because Z-Cardio is recognized as capable of monitoring only changes in stroke volume and 
cardiac output independent of the true value. 
6.1.2. Pharmacological Agents 
To assess whether the Z-Cardio algorithm is capable of monitoring changes in cardiac 
output, it was necessary to induce changes in cardiac output within the subject under 
investigation. Inotropic drugs by definition induce changes in myocardial contractility that 
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modulates cardiac output. Positive inotropes increase cardiac output while negative inotropes 
decrease cardiac output. Dopamine, a hormone and neurotransmitter, induces vasodilation, 
reduces peripheral vascular resistance, and decreases vascular blood pressure. The autonomic 
nervous systems compensates for these effects by increasing both heart rate and myocardial 
contractility that contribute to an acute increase in cardiac output. 
Metoprolol is a selective β1 receptor blocker that blocks the action of endogenous 
catecholamines that mediate the fight-or-flight response in most mammals [36]. By blocking 
the β1 receptor, nervous system stimulation is arrested, decreasing sympathetic response, heart 
rate, and cardiac output. Stimulating a living subject with dopamine or metoprolol will induce 
an increase or decrease cardiac output, respectively. Both drugs were approved for use in this 
study to assess whether the Z-Cardio algorithm could monitor both positive and negative 
changes in cardiac output. 
Acute studies are short-term evaluations of device or therapy performance prior to 
animal sacrifice. At the conclusion of an acute study, the subject is terminated by a single bolus 
dose of Euthasol, a chemical barbiturate and central nervous system depressant [37]. Euthasol 
was approved by the institutional review boards of Micro Systems Engineering, Inc. and 
Legacy Research Institute as a humane means of inducing euthanasia. 
6.2. Z-Cardio Animal Study Results 
Stroke volume changes measured by both PiCCO and Z-Cardio are shown below in 
Figure 23 on the left and right, respectively. Notice three distinct sharp increases in stroke 
volume preceding a sharp decrease, changes that were expected as part of the study design.  
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Figure 23: Stroke volume changes measured over time by both the PiCCO monitor (left) and Z-Cardio (right) 
Shown above, the two estimates of stroke volume possess a high degree of similarity. 
In each estimate, three distinct peaks correspond to three distinct bolus doses of dopamine. 
The measurements above are derived from stroke volume estimations of individual cardiac 
contractions. Multiplied by heart rate, cardiac output estimations were derived. Cardiac output 
estimations made by PiCCO and Z-Cardio are shown in Figure 24 on the left and right, 
respectively. 
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Figure 24: Cardiac output changes measured over time by both the PiCCO monitor (left) and Z-Cardio (right) 
Despite the study protocol approval for the use of metoprolol to decrease cardiac 
output, at approximately 12 minutes following the beginning of data collection, the subject 
experienced a rapid decline in cardiac output not stimulated by pharmacological challenge. 
Under the suggestion of the attending veterinarian, the subject was euthanized prior to the 
administration of metoprolol. According to study protocol, the subject was euthanized with a 
bolus dose of Euthasol, a barbiturate that induces complete arrest of the central nervous 
system. 
Both PiCCO and Z-Cardio again possess high degrees of similarity in estimating 
cardiac output. As in estimations of stroke volume, both recordings clearly illustrate three 
distinct spike associated with three distinct doses of dopamine. Regression analysis quantifies 
the relationship between the PiCCO and the Z-Cardio cardiac output estimations. The linear 
model between cardiac output estimations made by PiCCO and Z-Cardio is shown below in 
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Figure 25.  
 
Figure 25: Regression analysis of cardiac output estimations by PiCCO and Z-Cardio 
According to the linear model, the correlation coefficient between the gold standard, 
PiCCO, and Z-Cardio is 0.923 with an R2 value of 0.917, indicating a moderately strong 
correlation between the two measurements.   
6.3. Anomalies, Weaknesses, and Interpretations 
Although promising, the results presented in this thesis are subject to anomalies and 
weaknesses. Most notably, the results presented here are dependent on the PiCCO 
thermodilution monitor as the gold standard employed for comparison. Any conclusions 
derived from these results are therefore dependent on the reliability of the PiCCO monitor. 
Studies that seek to compare cardiac output monitors should be cautious of timely calibration 
of thermodilution monitors  
Additionally, the PiCCO monitor does not report cardiac output or stroke volume 
when the cardiac output index is less than 3.0 l/min/m2, evident from the data presented. This 
limitation does not appear to be present in Z-Cardio; this partially accounts for discrepancies 
in the results but may lend credence to Z-Cardio as being an appropriate monitoring solution 
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for patients with exceptionally low cardiac output who ironically are most in need of quality 
monitoring support. More extensive characterization is required to establish an appropriate 
range of measurable values for this technology.  
While the study protocol was designed to induce a broad range of cardiac output in a 
single subject, more could be done to achieve a greater range of cardiac output changes. 
Ideally, changes in cardiac output could be set and held for an arbitrary duration. At present, 
the ideal means of controlling cardiac output to this degree would require a calibrated and 
programmable heart bypass machine and a massively invasive procedure. Whether feasible or 
not, alternative methods of inducing changes in cardiac output within a subject should be 
explored for future research. 
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7. Conclusions 
This thesis has described the background, hardware, theory, and algorithm necessary 
to monitor changes in cardiac output, as well as a bench-top intracardiac simulator used in 
refining the proposed algorithm and results obtained from an in vivo evaluation of the proposed 
cardiac output monitoring system. This thesis has employed sound engineering methodology 
to develop and assess a novel medical signal processing technology. However, the proposed 
system is far from being deployable within a human subject. The following potential avenues 
for further research are necessary to bring the algorithm nearer to a state sufficient for human 
evaluation. 
7.1. Further Research 
Further development of the Z-Cardio system and algorithm is required before the 
concept presented in this thesis is ready for human evaluation. The following research paths 
should be considered before advancing this technology beyond the proof-of-concept stage. 
1. The procedures presented in this thesis could be executed while employing a more 
modern gold standard, such as echocardiography, in assessing how accurately the Z-
Cardio algorithm monitors changes in cardiac output. 
2. Translate the analog front-end filter into a prototype PCB, rewrite the Z-Cardio 
algorithm into C and onto an embedded chip, thereby eliminating the need for the 
wired iLP and extraneous hardware, such as the DAQ. Thorough design verification 
and validation of implantable firmware is required prior to deployment within a living 
subject. Additionally, requisite power consumption requirements should be 
characterized to ensure appropriate battery life of an implantable prototype device. 
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3. Following conversion of the concept onto an embedded platform, a chronic grow-in 
assessment study must evaluate how well the algorithm performs over time as scar 
tissue and tissue capsule form around the iLP as part of the body’s foreign body 
response. 
4. Invert the concept by generating a high frequency voltage source from the iLP and 
monitoring changes in transthoracic impedance from outside the body, thereby off-
loading the signal processing requirements from the embedded iLP and onto external 
hardware.  
5. Assess how cardiac output monitoring differs amongst individuals of different body 
types. While this question cannot be answered without larger scale studies, assessment 
of body type impact on algorithm performance will be necessary for future approval. 
6. If further development of the D.I.C.E. simulator is required, consider replacing the 
hand pump with an electromechanical actuator for more consistent reproduction of 
compression dynamics. 
7.2. Concluding Remarks 
The design presented within this thesis demonstrates that an implantable device within 
the heart, such as a cardiac pacemaker, is capable of monitoring changes in cardiac output. 
Although more research is required before this type of technology is ready for chronic human 
implant, this promising proof of concept may pave the way for a revolution in cardiac pacing 
technology. An intelligent pacemaker may have the capability to automatically optimize pacing 
parameters by leveraging cardiac output maximization as a cost function.  
Ultimately, the concept developed in this thesis is nothing more than another tool in 
the vast arsenal afforded to the modern physician and cardiologist. Like any tool, the value is 
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dependent on the balance between the tool’s strengths and weakness and how they compare 
to similar tools in the physician’s toolbox. Launching this type of tool into the marketplace 
will require adherence to strict design requirements. Defining design requirements for the Z-
Cardio algorithm will likely require substantial input from practicing clinicians, physicians, 
cardiologists, and nurses to better equip the design for clinical deployment. Although these 
requirements have not yet been investigated, substantial review of demonstrated performance 
would be required for most future development. Nevertheless, the groundwork presented 
herein may serve as a promising foundation for future medical applications and cardiac output 
monitoring solutions for intracardiac medical devices.  
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Appendix A: D.I.C.E. Design Drawing 
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Appendix B: In Vivo Data Collection Study Protocol 
The following procedures were designed to obtain data from an implanted wired iLP 
device while pharmacologically modulating subject stroke volume and cardiac output.. This 
protocol was executed as part of MSEI internal acute study ARC-2013-009 at Legacy Research 
Institute, Department of Comparative Medicine in Portland, Oregon. The study was an acute, 
non-survival study. The protocol was executed on one subject.  
Justification of Testing System and Animal Arrangements 
Investigations focused on the features and functionality of non-approved, Class-III 
medical devices are not always possible in humans without first establishing their safety and 
utility in an animal model. Extensive investigations into features and functionality using in 
vitro and heart model simulators reduce and refine the experimental model and prototypes. 
Yet, present models do not accurately simulate the in vivo cardiac function when integrated 
with the circulatory system and autonomic nervous system. 
Swine (Sus scrofa domestica) is an established animal model for cardiovascular device 
research. The anatomical and physiological similarity between the human cardiovascular 
system and that of a swine allows the swine to accommodate the necessary instrumentation 
while providing accurate and thorough evaluations of medical devices prior to human 
implantation.  
Prior to enrollment in the study, animals undergo medical examinations after their 
arrival (entrance exam) and after the acclimatization period. This process helps to ensure only 
healthy animals undergo experimental procedures. The breeder will provide health certificates 
for the animal. If during the acclimatization period a veterinarian deems medical treatment 
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necessary, a member of the facility’s staff will inform the sponsor immediately. The treated 
animal’s documentation will record the type of medication/intervention, course of treatment, 
and reason for the intervention. 
Before the animal arrives, treatment of the enclosure will conform to the facility’s 
standard operating procedure (SOP). It is the intent of the study to house animals in a group 
enclosure. However, transfer of animals to a solitary enclosure may occur, as deemed necessary 
by the veterinarian. The room temperature will be between 21.1 ± 2.2°C. The relative humidity 
of the room is maintained between 40% and 70%. Values outside these ranges may occur 
occasionally during extreme climatic conditions. Artificial light is set to provide a 12-14 hour 
light cycle, and a 10-12 hour dark cycle. The air supply is 100% fresh (not re-circulated). 
Assessment of ventilation rates occur on an annual basis and following major construction. 
Swine pens are spot cleaned daily with complete bedding replacement weekly. 
Each subject shall receive Purina Mills® Lab Porcine Grower Diet 5084. 
Administration of the diet (approximate amount 3-5% of body weight per day) occurs as a 
split ration twice daily, and as a full ration once daily on weekends. Inspections of feedbags 
occur upon delivery for evidence of damage. Feed or bags found to be grossly contaminated, 
damaged, or repaired are not eligible for use. All food must be no more than 180 days past the 
milling date. Tap water is continuously available (ad libitum) from an automatic watering 
system until the night before the surgical procedure. On a monthly schedule, water quality 
undergoes a documented assessment by the Department of Comparative Medicine staff. 
The subject will not have access to food or water for no less than 12 hours and no 
more than 18 hours before the start of the study to reduce the risk of aspiration. These times 
are subject to change at the veterinarian’s discretion. Prior to the induction of anesthesia, the 
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subject will receive a weight-adjusted subcutaneous dose of tiletamine/zolazepam and 
atropine as a pre-anesthetic and sedative. Transfer to the laboratory will occur once the 
sedatives have taken effect. In the laboratory, the subject will undergo intubation and 
anesthetization via IV introduction of telazol and atropine with or without carporfen or 
buprenorphrine. To maintain anesthesia during the experimental procedure, the subject will 
receive a continuous flow of oxygen mixed with 0.5-5.0% Isoflourane by volume, via the 
intubation tube. Inserting at least one IV line into the ear vein will allow for the administration 
and maintenance of fluids. Continuously warming IV fluids and providing a warming pad 
underneath the subject provide maintenance and regulation of the subject’s body temperature. 
Further, a warming blanket is available as support if the subject requires additional assistance 
in maintaining physiologically healthy body temperatures. 
Upon completion of experimental procedures, the subject will receive a barbiturate 
(Euthasol - 1mL/5kg – IV), or another method which complies to veterinarian 
recommendation and IACUC (Institutional Animal Care and Use Committee) standards. 
Assessment of the subject’s ECG, respiration, pupil dilation, and cardiac activity will confirm 
euthanasia prior to the initiation of the necropsy. Following the conclusion of testing, an 
explantation procedure for the heart will begin. The explanted material may include the 
following: 
o The Heart 
o 3±3cm of Inferior Vena Cava 
o 3±3cm of Superior Vena Cava 
o 3±3cm of Pulmonary Artery 
o 3±3cm of Pulmonary Vein 
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o 3±3cm of Aorta  
Upon explant, the heart will undergo dissection and examination. Visual observations, 
notes, and photographs will record the implantation procedure and tool removal. If necessary, 
tissue samples will be collected and transported back to Biotronik, Inc./Micro Systems 
Engineering, Inc. in an isotonic saline bath or in formalin or sent to a histo-pathologist for 
analysis. 
Throughout the study, pharmacological support may be administered to support the 
subject’s vitals or to achieve a desired physiological effect. Table 2 lists drugs available to 
support the subject as needed. The name, pharmacological family, quantity available, dosage, 
anticipated duration of effect, and the desired effect of each drug is listed in the table.  
Table 2: Pharmacological drugs administered as part of this study 
Name Family Quantity Dose 
Duration 
of Effect 
Desired Effect 
Dopamine 
Sympathomimetic 
Agonist 
3 Vials 
2 to 20 µg/kg/min 
IV push doses 1mg, 
2mg, 3mg (6mg max) to 
CVP 
Vasopressive dose 15 to 
50ug/kg/min 
<10 Mins 
Positive 
Chronotrope 
Positive Inotrope 
Metoprolol 
Sympathomimetic 
Antagonist (β-
blocker) 
120 mg 
1 to 5 mg / min 
(7 minute max.) 
IV push doses 5mg, 
10mg, 10mg (25mg 
max) to CVP 
>120 
Mins 
Negative 
Chronotrope 
Negative Intrope 
Justification of Test Hardware Design 
Surface electrodes will transmit a voltage at frequency between 100 and 400 kHz across 
the thorax while the subject’s stroke volume is pharmacologically modulated. Raw data will be 
streamed continuously to disk by a National Instruments data acquisition system (NIDAQ) 
USB-6343 through MATLAB. The NIDAQ will connect to both proximal ring and tip of the 
wired iLP. The National Instruments system will record data at between 100 and 500 kHz at 
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16 bit resolution. The data file will be stored to and saved directly onto the laptop’s hard drive.  
A wired iLP device possesses two electrodes at both the tip and the hitch. The tip and 
hitch are connected to the terminal by a pair of 50 centimeter drawn filled tube (DFT) wires. 
The proximal ends of the wires connect to a standard IS-1 pacemaker lead terminal. 
Measurements are recorded from the tip (the positive terminal at the iLP screw) and the ring 
(the negative terminal at the iLP fin) of the terminal. Measuring voltage across the terminal 
leads is analogous to measuring voltage across the iLP. 
Equipment 
The data collection study will employ specific hardware and software to collect and 
store the data obtained from this study.  
Table 3: Quantity and equipment employed throughout the preliminary data collection study 
Quantity Device 
1 Laptop with Windows 7 running MATLAB 
1 National Instruments USB-6343 Data Acquisition System 
1 Pulsion Medical Systems PiCCO2 Monitor with Cables and Catheters 
1 Isolated Z-COMM Signal Transmitter Board 
2 Silver chloride Surface Electrodes 
1 Extension Cord 
1 Power Strip 
1 External Hard Drive (500 GB) 
1 Wired iLP Device 
1 iLP Deployment Tool 
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Appendix C: Z-Cardio Data Collection Procedure 
1. Prepare 500mL cold saline and keep on ice 
2. Shave the subject’s chest and clean the skin with a diluted isopropyl alcohol solution 
3. Perform bilateral jugular cut downs at the left and right jugular furrow 
4. Isolate both the left and right external jugular veins, ligate the vessels, pack incision 
with moistened gauze as needed 
5. Implant a wired iLP device per pre-defined iLP implantation procedure 
6. Using fluoroscopy, identify the position and orientation of the iLP within the heart 
7. Mark the skin surface with a marker on both coronal and sagittal planes 
8. Assemble the PiCCO cardiac output monitoring system 
9. Implant PiCCO thermodilution catheters per pre-defined PiCCO setup procedure 
10. Once catheterized, calibrate the PiCCO monitor via administration of three cold saline 
boluses 
11. Place two transmitting ECG surface electrodes on the subject’s chest axially aligned 
with the iLP device. The electrodes should be separated by approximately twice the 
depth of the iLP from the skin surface 
12. Connect the terminal ends of the wired iLP to the NIDAQ 
13. Connect the transmitting electrodes to an isolated battery-powered Z-COMM 
function-generating programmer board  
14. Set the sinusoidal transmission frequency to 100 kHz at amplitude such that measured 
voltage amplitude at the implant device is approximately 15 mV. 
15. Simultaneously begin streaming data from both the PiCCO monitor and the NIDAQ 
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via MATLAB 
16. Wait approximately 1 minute to collect baseline data 
17. Administer IV push doses 1mg of dopamine to CVP to increase subject inotropy.  
a. Observe any changes in heart rate, strove volume, or cardiac output  
b. Wait for cardiac output to return to near baseline or 5 minutes, whichever 
comes first 
18. Administer IV push doses 2mg of dopamine to CVP to increase subject inotropy.  
a. Observe any changes in heart rate, strove volume, or cardiac output  
b. Wait for cardiac output to return to near baseline or 5 minutes, whichever 
comes first 
19. Administer IV push doses 3mg of dopamine to CVP to increase subject inotropy.  
a. Observe any changes in heart rate, strove volume, or cardiac output  
b. Wait for cardiac output to return to near baseline or 5 minutes, whichever 
comes first 
20. Following the maximum dose of dopamine, allow the vital signs to approach baseline 
values 
21. Administer IV push doses 25mg max to CVP of metoprolol to reduce subject 
inotropy. 
22. Once vital signs have stabilized under metoprolol, or after 5 minutes, administer 1 
mL/5 kg of Euthasol to terminate the subject. 
23. Once the animal is declared deceased, stop recording from both PiCCO and NIDAQ 
 
